381 related articles for article (PubMed ID: 18550651)
1. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.
Ruggenenti P; Bettinaglio P; Pinares F; Remuzzi G
Clin J Am Soc Nephrol; 2008 Sep; 3(5):1511-25. PubMed ID: 18550651
[TBL] [Abstract][Full Text] [Related]
2. ACE insertion/deletion polymorphism and diabetic nephropathy: clinical implications of genetic information.
Ha SK
J Diabetes Res; 2014; 2014():846068. PubMed ID: 25587546
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
[TBL] [Abstract][Full Text] [Related]
5. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.
Perna A; Ruggenenti P; Testa A; Spoto B; Benini R; Misefari V; Remuzzi G; Zoccali C
Kidney Int; 2000 Jan; 57(1):274-81. PubMed ID: 10620209
[TBL] [Abstract][Full Text] [Related]
6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
7. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy.
Ahluwalia TS; Ahuja M; Rai TS; Kohli HS; Bhansali A; Sud K; Khullar M
DNA Cell Biol; 2009 Mar; 28(3):141-50. PubMed ID: 19108684
[TBL] [Abstract][Full Text] [Related]
8. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Ruggenenti P; Cravedi P; Remuzzi G
Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
[TBL] [Abstract][Full Text] [Related]
9. The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.
Rahimi Z; Felehgari V; Rahimi M; Mozafari H; Yari K; Vaisi-Raygani A; Rezaei M; Malek-Khosravi S; Khazaie H
Mol Biol Rep; 2011 Mar; 38(3):2117-23. PubMed ID: 20853144
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
[TBL] [Abstract][Full Text] [Related]
11. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.
Rudnicki M; Mayer G
Pharmacogenomics; 2009 Mar; 10(3):463-76. PubMed ID: 19290794
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study.
van der Knaap R; Siemes C; Coebergh JW; van Duijn CM; Hofman A; Stricker BH
Cancer; 2008 Feb; 112(4):748-57. PubMed ID: 18181094
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic implications of ACE-gene polymorphism].
Dimopoulos-Xicki L; Haas M
Wien Med Wochenschr; 2005 Feb; 155(3-4):50-3. PubMed ID: 15791776
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism.
So WY; Ma RC; Ozaki R; Tong PC; Ng MC; Ho CS; Lam CW; Chow CC; Chan WB; Kong AP; Chan JC
Kidney Int; 2006 Apr; 69(8):1438-43. PubMed ID: 16395257
[TBL] [Abstract][Full Text] [Related]
15. [Association between ACE gene polymorphism and therapeutic responsiveness of ACEI in diabetic nephropathy].
Wang L; Pan CY; Hu W
Zhonghua Yi Xue Za Zhi; 1998 May; 78(5):372-4. PubMed ID: 10923445
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
Jacobsen P; Rossing K; Rossing P; Tarnow L; Mallet C; Poirier O; Cambien F; Parving HH
Kidney Int; 1998 Apr; 53(4):1002-6. PubMed ID: 9551410
[TBL] [Abstract][Full Text] [Related]
17. [Diabetic nephropathy and ACE inhibitors].
Amann B
Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
[TBL] [Abstract][Full Text] [Related]
18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
19. [Association of the renin-angiotensin system gene polymorphism with nephropathy in type II diabetes].
Buraczyńska M; Ksiazek P; Łopatyński J; Spasiewicz D; Nowicka T; Ksiazek A
Pol Arch Med Wewn; 2002 Aug; 108(2):725-30. PubMed ID: 12476891
[TBL] [Abstract][Full Text] [Related]
20. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen).
Ruggenenti P; Perna A; Zoccali C; Gherardi G; Benini R; Testa A; Remuzzi G
J Am Soc Nephrol; 2000 Jan; 11(1):88-96. PubMed ID: 10616844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
